Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lam

Showing results (551-560 of 1,163) with videos related to

Pageof 117
Sort By:
The New England Journal of Medicine|July 2, 2021
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesHertzel C Gerstein, Naveed Sattar, Julio Rosenstock, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 15, 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trialJoão Pedro Ferreira, John G Cleland, Carolyn S P Lam, et al.
The American Journal of Cardiology|October 2, 2018
Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection FractionAndrew P Ambrosy, Hillary Mulder, Adrian Coles, et al.
American Journal of Respiratory Cell and Molecular Biology|July 27, 2013
Asbestos-induced alveolar epithelial cell apoptosis. The role of endoplasmic reticulum stress responseDavid W Kamp, Gang Liu, Paul Cheresh, et al.
Clinical Chemistry and Laboratory Medicine|October 7, 2018
Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB)Amy K Saenger, Allan S Jaffe, Richard Body, et al.
Journal of the American College of Cardiology|March 16, 2018
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 StudyMikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, et al.
Diabetes, Obesity & Metabolism|July 2, 2026
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O TrialDaniel Raaschou-Oddershede, Christine R Schwarz, Tanya Kovalova, et al.
Journal of Cardiac Failure|March 1, 2021
Generalizability of HFA-PEFF and H<sub>2</sub>FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEFU L Faxen, Ashwin Venkateshvaran, Sanjiv J Shah, et al.
Scientific Reports|May 20, 2022
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fractionNicolas Girerd, John Cleland, Stefan D Anker, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2019
IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid CarcinomaSiao Ting Chong, Khee Ming Tan, Catherine Y L Kok, et al.
Pageof 117

Showing results (551-560 of 1,163) with videos related to

Sort By:
Pageof 117
The New England Journal of Medicine|July 2, 2021
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesHertzel C Gerstein, Naveed Sattar, Julio Rosenstock, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 15, 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trialJoão Pedro Ferreira, John G Cleland, Carolyn S P Lam, et al.
The American Journal of Cardiology|October 2, 2018
Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection FractionAndrew P Ambrosy, Hillary Mulder, Adrian Coles, et al.
American Journal of Respiratory Cell and Molecular Biology|July 27, 2013
Asbestos-induced alveolar epithelial cell apoptosis. The role of endoplasmic reticulum stress responseDavid W Kamp, Gang Liu, Paul Cheresh, et al.
Clinical Chemistry and Laboratory Medicine|October 7, 2018
Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB)Amy K Saenger, Allan S Jaffe, Richard Body, et al.
Journal of the American College of Cardiology|March 16, 2018
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 StudyMikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, et al.
Diabetes, Obesity & Metabolism|July 2, 2026
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O TrialDaniel Raaschou-Oddershede, Christine R Schwarz, Tanya Kovalova, et al.
Journal of Cardiac Failure|March 1, 2021
Generalizability of HFA-PEFF and H<sub>2</sub>FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEFU L Faxen, Ashwin Venkateshvaran, Sanjiv J Shah, et al.
Scientific Reports|May 20, 2022
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fractionNicolas Girerd, John Cleland, Stefan D Anker, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2019
IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid CarcinomaSiao Ting Chong, Khee Ming Tan, Catherine Y L Kok, et al.
Pageof 117